Role of IV Calcium to Prevent Diltiazem-related Hypotension
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 217 participants.
Also called NCT06494007
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 217 participants
- Sponsor
- Haseki Training and Research Hospital
- Registry
-
NCT06494007
-
- Other papers using this trial's data
- Reducing diltiazem-related hypotension in atrial fibrillation: Role of pretreatment intravenous calcium
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Türkiye
- Registry status
- Completed
Technical summary
Registry record NCT06494007. Randomized; triple masking; primary purpose prevention. Start 2023-01-01 (actual); primary completion 2024-06-01 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Role of IV Calcium to Prevent Diltiazem-related Hypotension
- Acronym
- AFstd
- Condition
- Atrial Fibrillation
- Condition
- Rapid Ventricular Response
- Condition
- Hypotension Drug-Induced
- Intervention (Drug)
- Sodium chloride
- Intervention (Drug)
- 90 mg of calcium
- Intervention (Drug)
- 180 mg Calcium
- Lead sponsor
- Haseki Training and Research Hospital
Record details
- Record id
cardio:ct-nct06494007- Content hash
9ece17858f1c7c3e2b15dc0baae286f492a2f3a79d14a97dff9cccb7beb68f64